Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-11-28

Clinical Trial Update: Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) [Phase 3]

View source ↗

Summary

Phase 3 KEYNOTE-189 study evaluating pembrolizumab plus pemetrexed and platinum versus chemotherapy alone in first-line metastatic nonsquamous non-small cell lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alimta (pemetrexed)
  • CARBOPLATIN (Carboplatin)
  • KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-Small-Cell Lung Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2018-11-28